Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Boehringer Ingelheim
UBS
Johnson and Johnson
Cerilliant
Covington
Accenture
McKesson

Generated: December 13, 2018

DrugPatentWatch Database Preview

REBIF Drug Profile

« Back to Dashboard

Summary for Tradename: REBIF
Patents:82
Applicants:1
BLAs:1
Suppliers: see list1
Drug Prices: Drug price information for REBIF
Pharmacology for REBIF

US Patents for REBIF

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07 ➤ Try a Free Trial Bayer Intellectual Property GMBH (Monheim, DE) ➤ Try a Free Trial RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07 ➤ Try a Free Trial Schutzer; Steven E. (New York, NY) ➤ Try a Free Trial RX search
Serono Inc REBIF interferon beta-1a SYRINGE 103780 002 2002-03-07 ➤ Try a Free Trial MERCK SERONO SA (Coinsins, Vaud, CH) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for REBIF

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
315 Luxembourg ➤ Try a Free Trial PRODUCT NAME: PROCEDE DE TRAITEMENT DE LA SCLEROSE MULTIPLE - DACLIZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/16/1107
354 Luxembourg ➤ Try a Free Trial PRODUCT NAME: COBICISTAT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET ALAFENAMIDE DE TENOFOVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE D'ALAFENAMIDE DE TENOFOVIR; AUTHORISATION NUMBER AND DATE: EU/1/15/1061
90002-8 Sweden ➤ Try a Free Trial PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; REG. NO/DATE: EU/1/15/1025 20150715
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Dow
Express Scripts
Boehringer Ingelheim
Medtronic
Cerilliant
Johnson and Johnson
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.